Brief: Sino Biopharmaceutical Announces Exclusive License And Cooperation Deal With YZY Biopharma
08/10/2024 02:16
Oct 8 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK :
* SIGNING OF AN EXCLUSIVE LICENSE AND COOPERATION AGREEMENT
WITH
YZY BIOPHARMA
* UNIT WILL PAY APPROXIMATELY RMB315 MILLION AS UPFRONT
PAYMENT
* UNDER DEAL, UNIT WILL PAY SALES MILESTONE PAYMENTS OF UP
TO
RMB700 MILLION TO YZY BIOPHARMA
* UNIT OBTAINED LICENSE FOR DEVELOPMENT, COMMERCIALIZATION
OF M701
DEVELOPED BY YZY BIOPHARMA IN MAINLAND CHINA
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up